Prism is a biotechnology company that develops therapeutic drugs that cure intractable diseases using unique peptide mimic technology.
Prism BioLab has raised $10.2M in total funding. The most recent round was Series C. The last funding was announced in January 2024.
Prism BioLab's investors include Eli Lilly, Daiwa Corporate Investment, JAFCO, WM Partners, Eisai.
Prism BioLab is headquartered in Fujisawa, Japan.
Prism is a biotechnology company that develops therapeutic drugs that cure intractable diseases using unique peptide mimic technology.
Prism BioLab is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Prism BioLab — Funding & Investors." VCBacked, January 24, 2024, https://www.vcbacked.co/company/prism-biolab. Accessed July 30, 2026.
VCBacked. (2024). Prism BioLab — Funding & Investors. Retrieved July 30, 2026, from https://www.vcbacked.co/company/prism-biolab
{{cite web |title=Prism BioLab — Funding & Investors |url=https://www.vcbacked.co/company/prism-biolab |website=VCBacked |access-date=July 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated